deltatrials
Completed PHASE2 NCT00003114

Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease

Oral Combination Chemotherapy in the Treatment of AIDS-Associated Hodgkin's Disease

Sponsor: Case Comprehensive Cancer Center

Conditions Lymphoma
Interventions cyclophosphamide etoposide filgrastim lomustine procarbazine hydrochloride radiation therapy
Updated 6 times since 2017 Last updated: Jun 9, 2010 Started: Jul 31, 1997 Primary completion: Jun 30, 2002 Completion: Feb 28, 2003

This PHASE2 trial investigates Lymphoma and is currently completed. Case Comprehensive Cancer Center leads this study, which shows 6 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jul 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Case Comprehensive Cancer Center
  • National Cancer Institute (NCI)
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States